A Food and Drug Administration advisory panel on Thursday recommended the approval of Moderna’s mRNA-based flu shot for older adults.

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to start a public conversation about how mRNA technology can offer better ...

Moderna has countered a patent-infringement lawsuit brought by biotech company CureVac in Delaware federal court over its ...

MASSACHUSETTS - Advisers to the US Food and Drug Administration on June 18 backed approval of Moderna’s flu vaccine for adults aged 50 and older, saying its benefits outweigh the risks, boosting the ...

WASHINGTON (AP) — The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of ...

The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Messenger RNA technology, or mRNA, is widely ...

The FDA’s Vaccines and Related Biological Products Advisory Committee has unanimously backed Moderna’s mRNA-based flu shot, mFlusiva, for adults 50 and older, after phase 3 data showed it to be about ...

Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In a ...

Sanofi has sued Pfizer and Moderna , alleging that their COVID-19 vaccines infringe several of the French pharmaceutical ...